SYSTEMATIC REVIEW OF THE COST-EFFECTIVENESS OF ABEMACICLIB IN THE TREATMENT OF HR+/HER2− ADVANCED OR METASTATIC BREAST CANCER . YHCĐ [Internet]. 2026 Nov. 4 [cited 2026 Nov. 8];67(10). Available from: https://tapchiyhcd.vn/index.php/yhcd/article/view/6967